<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383108</url>
  </required_header>
  <id_info>
    <org_study_id>SMILE (PENTA 17)</org_study_id>
    <secondary_id>ANRS1 52</secondary_id>
    <nct_id>NCT02383108</nct_id>
  </id_info>
  <brief_title>Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children</brief_title>
  <acronym>SMILE</acronym>
  <official_title>A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MRC CTU at UCL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PHPT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PENTA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and&#xD;
      antiviral effect of current standard antiretroviral therapy compared to once daily integrase&#xD;
      inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically&#xD;
      suppressed paediatric participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two arm parallel group, non-inferiority, open-label, multi-centre, randomised controlled&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">August 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with HIV-1 RNA ever ≥ 50 c/mL (confirmed within 4 weeks)</measure>
    <time_frame>at any time up to week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HIV-1 RNA &lt; 50 c/mL</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HIV-1 RNA ≥ 50 c/mL</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients withHIV-1 RNA ≥ 400c/mL</measure>
    <time_frame>at week 24 and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with any grade 3 or 4 clinical adverse events (particularly lipodystrophy); any grade 3 or 4 laboratory adverse events</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All grade 3 or 4 laboratory adverse events</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any adverse event at least possibly related to study drugs or leading to treatment modifications</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new resistance mutations</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 (absolute and percentage)</measure>
    <time_frame>from baseline to weeks 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ART (defined as any change from the ART regimen at randomisation)</measure>
    <time_frame>at week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or recurrent CDC/WHO stage C or severe stage B event or death</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence as measured by questionnaire and visual analogue scale</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and quality of life over 48 weeks as assessed by patient completed questionnaires</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner scales (in participants aged over 8 years)</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of first menses</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Over 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>over 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Standard of Care group (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTG+DRV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG +DRV/r</intervention_name>
    <description>NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)</description>
    <arm_group_label>DTG+DRV/r</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)</description>
    <arm_group_label>Standard of Care group (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 infected children aged ≥ 12 years old and weighing ≥40kg* at the screening visit&#xD;
&#xD;
          2. Aged 12 to &lt; 18 years old**&#xD;
&#xD;
          3. Parents or guardians, and children where appropriate, willing and able to give&#xD;
             informed consent and to adhere to the protocol&#xD;
&#xD;
          4. Children must have all HIV-1 RNA viral loads &lt;50c/mL for at least 12 months with a&#xD;
             minimum of two separate results before screening.&#xD;
&#xD;
          5. Children on a 3-drug PI/r or NNRTI containing regimen for at least 24 weeks&#xD;
&#xD;
          6. Children/parents/guardians prepared to switch if randomised to once daily integrase&#xD;
             inhibitor + DRV/RTV arm&#xD;
&#xD;
          7. Children and parents prepared to restart the current ART regimen after simplification&#xD;
             if viral load restart criteria are met (see Section 5.5)&#xD;
&#xD;
          8. Be affiliated or beneficiary to Health Social security scheme (in countries where this&#xD;
             is mandatory)&#xD;
&#xD;
               -  Initially enrolment will be of participants ≥ 12 years old and ≥40kg only. DTG 50&#xD;
                  mg will be supplied by ViiV Healthcare.&#xD;
&#xD;
                    -  As more data become available on younger children, a protocol amendment is&#xD;
                       planned to include younger children and/or lower weight bands.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving or requiring agents with interactions with DRV, RTV, or any once daily&#xD;
             integrase inhibitor (Appendix 14)&#xD;
&#xD;
          2. Evidence of resistance to DRV or integrase inhibitors (for participants in clinical&#xD;
             sites where resistance testing is standard of care)&#xD;
&#xD;
          3. Previous exposure to integrase inhibitors for more than 2 weeks&#xD;
&#xD;
          4. Intercurrent illness (randomisation can take place after the illness resolves)&#xD;
&#xD;
          5. Creatinine ≥ 1.8ULN or ALT ≥ 5ULN or ALT ≥ 3ULN and bilirubin ≥2ULN at screening.&#xD;
&#xD;
          6. Patients with severe hepatic impairment or unstable liver disease (as defined by the&#xD;
             presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or&#xD;
             gastric varices, or persistent jaundice), known biliary abnormalities (with the&#xD;
             exception of Gilbert's syndrome or asymptomatic gallstones)&#xD;
&#xD;
          7. Diagnosis of tuberculosis and on anti-tuberculosis treatment (children can be enrolled&#xD;
             after successful tuberculosis treatment)&#xD;
&#xD;
          8. Hepatitis B or Hepatitis C co-infection&#xD;
&#xD;
          9. Pregnancy or risk of pregnancy in girls of child-bearing potential unless committed to&#xD;
             taking effective contraception&#xD;
&#xD;
         10. History or presence of known allergy or some other contraindication to the study drugs&#xD;
             or their components as described in the SmPC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Andrée Rosemon</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu - Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Mexico</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dona Estefânia - CHLC</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Materno-Infantil de Norte</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FAM-CRU</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHRU</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselpital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderspital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Chanthaburi</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalasin hospital</name>
      <address>
        <city>Kalasin</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khonkaen hospital</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao hospital</name>
      <address>
        <city>Phayao</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JCRC</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kryvyi Rih</name>
      <address>
        <city>Kryvyi Rih</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evelina Children Hospital, St Thomas's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

